<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30358609</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>25</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1533-4058</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>24</Day>                    </PubDate>                </JournalIssue>                <Title>Applied immunohistochemistry &amp; molecular morphology : AIMM</Title>                <ISOAbbreviation>Appl. Immunohistochem. Mol. Morphol.</ISOAbbreviation>            </Journal>            <ArticleTitle>Unexpected PAX8 Immunoreactivity in Metastatic High-grade Breast Cancer.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1097/PAI.0000000000000707</ELocationID>            <Abstract>                <AbstractText>Immunohistochemistry (IHC) is often critical for distinction between metastatic carcinomas of Mullerian organ and breast origin. Paired box family protein 8 (PAX8) has been described as a transcription factor highly specific to neoplasms derived from Mullerian organs, thyroid, and kidney. PAX8 IHC with polyclonal and monoclonal antibody reagents was performed on 27 primary and 22 metastatic breast carcinomas. Eight of 27 primary breast carcinomas (30%) were positive for PAX8 with the monoclonal antibody reagent only; 0 of 22 were polyclonal anti-PAX8 immunoreactive. Substantial numbers of metastases had positive immunoreactivity for polyclonal anti-PAX8 (23%). Each of these metastases and additional cases (45% total) also had positive immunoreactivity for monoclonal anti-PAX8, including 5 of 7 brain metastases. IHC with monoclonal anti-PAX8 was positive on 6 of 7 primary breast carcinomas corresponding to PAX8-positive metastases. Together, these results indicate a significant fraction of breast carcinoma metastases and corresponding primary neoplasms have immunoreactivity for PAX8, and positivity rates depend on the antibody used. Diagnoses of metastatic breast carcinoma were achieved with the aid of clinical history and additional IHC in cases of PAX8 immunoreactivity. Contextual interpretation is imperative for PAX8 IHC, particularly when the differential diagnosis includes metastatic breast carcinoma with limited diagnostic material available.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Kilgore</LastName>                    <ForeName>Mark R</ForeName>                    <Initials>MR</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology, University of Washington, Seattle, WA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bosch</LastName>                    <ForeName>Dustin E</ForeName>                    <Initials>DE</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Adamson</LastName>                    <ForeName>Kathi H</ForeName>                    <Initials>KH</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Swanson</LastName>                    <ForeName>Paul E</ForeName>                    <Initials>PE</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Dintzis</LastName>                    <ForeName>Suzanne M</ForeName>                    <Initials>SM</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Rendi</LastName>                    <ForeName>Mara H</ForeName>                    <Initials>MH</Initials>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>24</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Appl Immunohistochem Mol Morphol</MedlineTA>            <NlmUniqueID>100888796</NlmUniqueID>            <ISSNLinking>1533-4058</ISSNLinking>        </MedlineJournalInfo>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>26</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>26</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>26</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30358609</ArticleId>            <ArticleId IdType="doi">10.1097/PAI.0000000000000707</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>